T
Trefoil Therapeutics
Trefoil was founded to bring forward novel engineered FGF-1 compounds to treat endothelial cell mediated diseases
About Trefoil Therapeutics
Trefoil Therapeutics is a biotechnology company specializing in the development of regenerative pharmacologic treatments for corneal diseases. The company's core technology platform is based on engineered fibroblast growth factor 1 (eFGF1), which is designed to stimulate the proliferation and migration of corneal endothelial cells. Trefoil's lead candidate, TTHX1114, is an engineered form of FGF1 that is being developed as an intracameral injection. This treatment aims to address endothelial dystrophy, a leading cause of cornea transplantation surgeries, by promoting the healing of corneal endothelial lesions.
Trefoil operates in the biopharmaceutical market, targeting ophthalmologists and healthcare providers who treat corneal diseases. The company's business model involves the research, development, and eventual commercialization of its proprietary treatments. Revenue is generated through the sale of these pharmacologic treatments, as well as potential partnerships and licensing agreements with larger pharmaceutical companies.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Dec 2021 | $28M | $112M | Hatteras Venture Partners | ↗ |
| FundingOther financing | Jan 2020 | $0 | — | Solasta Ventures | — |
Growth signals
Latest recorded traffic for Trefoil Therapeutics is 1K monthly website visits, down 37.5% over the last three months. Trefoil Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Trefoil Therapeutics in the San Diego ecosystem
The Trefoil Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Hatteras Venture Partners
Aju IB Investment
ExSight Capital
Bios Partners
Correlation Ventures
Other known investors4 additional known investors
Florida State University
Solasta Ventures
University of California, Irvine
Washington University in St. Louis
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Trefoil Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Trefoil Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










